SciClone (SCLN) Issues Strong FY11, FY12 Revs Update

SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN) announced its anticipated full-year 2011 revenues and year-end cash position, and provided its 2012 initial revenue and year-end cash guidance as follows:

• For 2011, the Company anticipates revenues of approximately $134 million (unaudited) including revenues of NovaMed Pharmaceuticals, Inc. (NovaMed) following the acquisition in April 2011, a 57% increase over 2010. The Street sees revs of $132.6 million.
  
• Cash and investments are anticipated to be approximately $66 million (unaudited) at December 31, 2011, compared with $57 million at December 31, 2010. During 2011 the Company used cash of approximately $25 million (unaudited) for the acquisition of NovaMed and approximately $4 million (unaudited) for repurchases of Company Stock.
  
• The Company anticipates 2012 sales revenue of $165 to $170 million, approximately a 25% increase over 2011. The Street is modeling $165.6 million.
  
• The Company anticipates 2012 year-end cash and investments balances to be greater than $85 million excluding any impacts on cash balances associated with the Company's acquisition of new products and ongoing stock repurchase program.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance